Wiltrom Co. Ltd. · TPEX:6767
Wiltrom — Q3 2024 Earnings Presentation
20 slides from Wiltrom's earnings presentation, October 2025
Slide 1: Wiltrom Co., Ltd
Stock Number: 6767 Wiltrom Co., Ltd 0
Slide 2: Safe Harbor Notice
Safe Harbor Notice Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors sh
Slide 3: Outline
Outline Company Profile and Business Development Operational and Financial Overview Future Outlook and Key Takeaways 2
Slide 4: Company Profile
COMPANY PROFILE Minimally Invasive Spinal Surgery Platform - Comprehensive Care Solutions Company Portfolio • Establish: Dec. 2009 (A spin-off company from ITRI) • Paid in Capital: NTD$ 391,836,300 • Subsidiary: Wiltrom Inc. • Employee: 55 • A company devoted to MIS spinal surgery with a completed p
Slide 5: Wiltrom's Global Sales Territory
WILTROM’S GLOBAL SALES TERRITORY Actively Expand Overseas Markets Markert Size US$8.2B Markert Size US$1.15B Spinal Fusion Vertebral Augmentation System Tripod-Fix Interbody Fusion System Markert Size US$1.32B Bone Graft Substitute Bone Cement 4
Slide 6: Tripod-Fix
Tripod-Fix First expandable device focused on the “Wedge Fracture Treatment” 85% of VCFs are Wedge Fractures* One-piece design 3D Triangular Pyramid Vertebral compression fracture Expansion Cement (VCFs) injection Complete the surgery within 30 min *Ref. The Spine Journal , 2015, 15, 281–289 5
Slide 7: Market Growth Momentum
MARKET GROWTH MOMENTUM Driven by Tripod-Fix and Strategic Expansion in Europe Market Share Target : ▪ >10% Market Share in Germany (Europe’s Largest Market) ▪ ~10% Market Share Across Europe Extensive European Distribution Network ▪ Direct Sales (planning) : Germany ▪ Distributors : Covering 11 Euro
Slide 8: Tripod-Fix Global Growth Potential
Tripod-Fix GLOBAL GROWTH POTENTIAL 85% Growth in 2024 and Anticipate Robust Growth in 2025 Tripod-Fix GLOBAL SALES GROWTH TREND 5,000 4,500 Robust Growth 4,000 3,500 3,000 2,500 2,000 85% 1,500 2,316 35% Quantity (pcs) 1,000 500 1,248 923 0 2022 2023 2024 2025 Total 7 ®️2023 Wiltrom Inc. Company con
Slide 9: EUROSPINE 2024 Tripod-Fix Clinical Insight Symposium
EUROSPINE 2024 Tripod-Fix CLINCIAL INSIGHT SYMPOSIUM Vienna, Austria/ Oct. 3rd : 3 KOL Speakers from Germany and Taiwan and 50 participants Prof. Robert Pflugmacher Prof. Andreas Kurth Prof. Cheng-Li Lin ▪ Mechernich, Germany ▪ Frankfurt, Germany ▪ Tainan, Taiwan 8
Slide 10: EUROSPINE 2024 Clinical Insights Symposium: Prof. Dr. Pflugmacher
EUROSPINE 2024 Tripod-Fix CLINICAL INSIGHTS SYMPOSIUM Prof. Dr. Pflugmacher Highlighting Key Benefit of Tripod-Fix ▪ 2023 Top European Surgeon Award ▪ Stryker SpineJack (SAKOS) study PI ▪ Wiltrom PMCF study PI ▪ The pioneer in Europe for balloon kyphoplasty ▪ The most experienced Kyphoplasty surgeon
Slide 11: EUROSPINE 2024 Clinical Insight Symposium: KOL Speakers
EUROSPINE 2024 Tripod-Fix CLINCIAL INSIGHT SYMPOSIUM Vienna, Austria: Featured 3 KOL Speakers from Germany and Taiwan Prof. Dr. Pflugmacher : “Using Tripod-Fix you have more opportunities and in several fractures you have a better height restoration. The studies have shown, I mean we're still in the
Slide 12: Tripod-Fix First Large-Scale Cadaver Workshop in Europe
Tripod-Fix First Large-Scale Cadaver Workshop in Europe July 1st, Dr. Marcia Demonstrated in Verona, Italy and Shared Key Advantages 30 Participants from distributors of 6 European countries Dr. Stefano Marcia ▪ Stryker SpineJack (SAKOS) PI ▪ Head of Radiology at the SS. Trinità Hospital ▪ Specializ
Slide 13: Tripod-Fix Superior to SpineJack in Anterior Restoration
Tripod-Fix SUPERIOR TO SPINEJACK IN ANTERIOR RESTORATION One of The Best Third-gen Vertebral Augmentation 85% of VCFs are Wedge Fractures Vertebral Gen I -VP Gen II -KP Gen III - Fracture Pain Vertebral Anatomical Treatment treatment Augmentation Restoration Stryker acquired Vexim for $191 million i
Slide 14: Outline
Outline Company Profile and Business Development Operational and Financial Overview Future Outlook and Key Takeaways 13
Slide 15: Q1-Q3/2023 Financial Results
Q1-Q3/2023 FINANCIAL RESULTS Year-on-Year Revenue Growth (In Thousands of New Taiwan Dollars) Consolidated revenue 300,000 250,000 GROW 14.2% 240,364 200,000 210,540 150,000 100,000 50,000 * Clinical expenses will start in 0 2023 and peak in 2024, Q1-Q3/2023 Q1-Q3/2024 It is expected to end in 2025
Slide 16: Operating Revenue in Recent Years
OPERATING REVENUE IN RECENT YEARS Steady Revenue Growth (In Thousands of New Taiwan Dollars) 350,000 303,522 300,000 282,538 250,000 206,864 200,000 150,000 144,499 102,368 100,000 75,261 59,829 50,000 0 2018 2019 2020 2021 2022 2023 As As of Nov Nov2024 2024 15
Slide 17: Export Revenue Growth Rate of 122%
EXPORT REVENUE GROWTH RATE OF 122% Continued to Boost Overseas Revenue (In Thousands of New Taiwan Dollars) AS OF NOV 2023 AS OF NOV 2024 48,351 21,814 16% 8% Taiwan Taiwan Foreign Foreign 236,366 255,171 92% 84% ➢ Overall Overseas Revenue Increased by $26,537 Compared to the Same Period Last Year (
Slide 18: Outline
Outline Company Profile and Business Development Operational and Financial Overview Future Outlook and Key Takeaways 17
Slide 19: Completed a private fundraising of NT$270 million on 11/20/2024
Completed a private fundraising of NT$270 million on 11/20/2024 Expand the product line portfolio, continue to Strategic Lead Investors: screen star products to maintain the company's • Taiwan/U.S. medical industry cultivated growth momentum for 10+ years • Grasp industrial chain dynamics through in
Slide 20: Conclusion
Conclusion • Tripod-Fix global sales increased by 85% compared to last year • Overseas revenue sales increased by 122% compared to last year • We will continue to screen the three high-star products and establish solid local channel networking to drive the rapid growth of revenue 19